Alzheimer's disease is the most common neurodegenerative disorder, affecting nearly half a million Australians. It causes progressive memory loss, cognitive decline, and behavioural changes, eventually leading to a complete loss of independence. For families and carers, watching a loved one navigate this condition can be both emotionally and practically demanding.
While current treatments may offer only short-term relief, this trial is evaluating an investigational twice-daily oral capsule for its potential to support symptom management and slow cognitive decline over time, helping people with Alzheimer's maintain independence for longer.
treatment design
Participants will gradually increase their dose each week to reach the target dose over the 24-week treatment period, followed by a four-week follow-up. All participants may roll over into an additional 24-week treatment phase. All procedures will be explained clearly, and participants and their carers can ask questions at any time.
